Aim: The incidence rate of small-size (T1) early-stage breast cancer (EBC) has increased. The risk of relapse is low, but there is a growing interest in identifying traditional and new prognostic factors to optimize therapeutic management. Patients with T1 EBC, especially if node-negative (N0), are excluded from tumor gene expression profiling due to the cost of this procedure. Immunohistochemistry (IHC)-based classification of breast cancer subtypes with confirmed prognostic and therapeutic implication is therefore recommended. Methods: We reviewed the records of 511 patients diagnosed with T1 EBC referred to our oncology unit for adjuvant therapy. This retrospective study evaluated the different long-term clinical outcomes over 15 years and correlated with traditional (T, N, ER and PgR, Ki-67, HER2) and surrogate molecular subtype classification of the tumors using IHC prognostic factors. In the overall population, the significant prognostic factors at 5 years were N0 vs. N1 ( p = 0.05), PgR <20% vs. PgR >20% ( p = 0.03), Ki-67 index <20% vs. Ki-67>20% ( p = 0.04) and Luminal A vs. Luminal B HER2 negative ( p = 0.05). At 15 years of follow-up, only Ki-67 index confirmed its prognostic value ( p = 0.04). In the N0 subgroup of patients DFS curves were significantly different for Ki-67 index <20% vs. Ki-67 >20% both at 5-year ( p = 0.01) and 15-year follow-up ( p = 0.03). Conclusions: The DFS curves of T1 EBC patients at 5 years underline the prognostic relevance of the cut-off of 20%, both for PgR expression and Ki-67 index as well as IHC-based molecular subtypes Luminal A vs. Luminal B HER2 negative. With regard to long-term outcome, only Ki67-index seems to be useful for identifying different prognostic tumor subgroups. These results were particularly important to improving current management of N0 EBC patients with different risk factors. Disclosure: All authors have declared no conflicts of interest.
